July 17, 2008
EpiCept and GNI Join Hands to Develop Hepatitis Drug in Asia
GNI and EpiCept have reached an agreement to develop a new therapeutic drug, EP1013, in Asia, Australia, and New Zealand, for late-stage viral infection-induced hepatitis.
Under the agreement, EpiCept will retain the rights in the rest of the world. GNI's wholly owned subsidiary, Shanghai Genomics, will start preparation for pre-investigational new drug (IND) application and clinical development in China immediately.
Jack Talley, president and CEO of EpiCept, said: "We are pleased to establish this collaboration to accelerate the development of EP1013 for a therapeutic area which is outside of our core focus areas in oncology and pain management. Caspase inhibitors may provide a new therapeutic modality for the treatment of degenerative diseases that involve apoptotic cell death."